- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02099851
Endovascular Carotid Body Ablation in Patients With Treatment- Resistant Hypertension: A Safety and Feasibility Study
October 14, 2016 updated by: Noblewell
Endovascular Carotid Body Ablation in Patients With Treatment- Resistant Hypertension: A Safety and Feasibility Study.
This is a prospective, observational, multicenter trial to evaluate the safety and feasibility of selective endovascular unilateral carotid body ablation in patients with treatment-resistant hypertension.
All patients will be followed for two (2) years following treatment.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
The investigators propose a new method of treatment, unilateral carotid body ablation, for treatment- resistant hypertensive patients to restore more normal blood pressure control, which will reduce cardiovascular morbidity and mortality in these patients.
This strategy will increase the number of therapeutic options available to many patients and their physicians as well as offering the potential of normal blood pressure to those patients in whom blood pressure remains elevated despite vigorous, drug or device based therapies.
Study Type
Interventional
Enrollment (Actual)
6
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Prague, Czech Republic, 150 30
- Na Homolce Hospital, Roentgenova 2
-
-
-
-
-
Gdansk, Poland, 80-952
- Department of Hypertension and Diabetology, Medical University of Gdansk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age of participants will be 18-75 years.
- Treatment-resistant hypertensive subjects on medical management.
- Office systolic blood pressure (oBP) ≥ 160mmHg.
- Daytime mean ambulatory BP (ABPM) ≥ 140 mmHg.
- Persistent hypertension on at least three anti-hypertensive medications, including a diuretic, at stable, maximum tolerated dose within the last 90 days.
- No evidence for causes of secondary HTN (hypertension ) following thorough clinical assessment.
- At least one carotid body detected in CT angiography of the neck, defined as an hyper-enhanced ovoid structure strongly located poster-medially from the area of carotid bifurcation.
- Ability to give and giving informed consent to participate in the study.
- Women of child-bearing potential have a negative pregnancy test.
Exclusion Criteria:
- Calculated GFR (glomerular filtration rate) < 30ml/min/m2
- Obstructive carotid atherosclerotic disease which precludes safe delivery of ablation catheter or performance of ablation
- Must be at least 6 months post renal denervation therapy.
- Oxygen saturation at rest below 92%.
- Requirement for oxygen therapy to maintain oxygen saturation.
- Severe untreated obstructive sleep apnea (defined as an apnea-hypopnea index (AHI) ≥ 30/hour during Polysomnography associated with an average minimum oxygen desaturation of < 85%.
- Patients wish to participate in mountain climbing, sky diving or free diving.
- Pregnancy or anticipation of pregnancy.
- Acute coronary syndrome or unstable angina < 6 months before scheduled procedure.
- History of repeated episodes of hypoglycemia with hypoglycemic unawareness.
- Known diabetic autonomic neuropathy.
- History of, or current atrial fibrillation (AF).
- Life expectancy of less than 24 months due to other disease.
- Intravenous or inhaled recreational drug use.
- Excessive use of alcohol or sedatives (alcohol intake > 28 units/week).
- Morbid obesity (BMI >40).
- Febrile illness within two weeks of participation.
- History of Stroke, transient ischaemic attack (TIA) or significant chronic neurological condition in medical history.
- History of spontaneous intracranial hemorrhage within past 12 months.
- Unable to tolerate exposure to the radiopaque contrast agent.
- Unable to tolerate aspirin and/or other anti-coagulation; anti-platelet medication.
- Femoral arterial access is not possible.
- Presence of carotid artery dissection prior to the index procedure.
- Atherosclerotic disease involving vessels adjoining the carotid body, marked vessel tortuosity or other anatomical findings that preclude safe placement of the guiding catheter or the investigational system, and the delivery of RF energy.
- Carotid body is not within reach of the investigational system due to position within the carotid bifurcation or distance of the CB (carotid body) from the femoral access point.
- Other abnormal angiographic findings that indicate the patient is at risk of a stroke, such as carotid or intracranial aneurysm, arteriovenous malformation (AVM), other developmental or traumatic vascular lesion or tumor.
- Dementia or confusion precluding the patient's full understanding of the information required for informed consent and full participation in the study.
- Unable to attend schedule follow up appointments at one (1)_month, three (3) months, six (6) months, one (1) year and two (2) years post treatment.
- History of gastrointestinal bleeding within the last six (6) months.
- Active or treated malignancies in the last twelve (12) months.
- Patient is participating in another clinical study for which follow-up is currently on going.
- Patient with non-cardiac co-morbidities and life expectancy < 2 year.
- Patient has a condition that, in the opinion of the Investigator, precludes participation, including willingness to comply with all follow-up procedures.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Carotid body ablation
Patients undergoing the unilateral endovascular ablation of the right or left carotid body.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: 3 months
|
Safety and feasibility of selective endovascular unilateral carotid body ablation in patients with treatment-resistant hypertension employing a radiofrequency catheter designed specifically for this indication.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Blood Pressure
Time Frame: 3 months
|
Change from Baseline Blood Pressure at 3 months
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2014
Primary Completion (ANTICIPATED)
December 1, 2016
Study Registration Dates
First Submitted
March 26, 2014
First Submitted That Met QC Criteria
March 28, 2014
First Posted (ESTIMATE)
March 31, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
October 17, 2016
Last Update Submitted That Met QC Criteria
October 14, 2016
Last Verified
October 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL1003-CIBIEM
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BayerCompletedPrimary HypertensionChina
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Carotid body ablation (Cibiem)
-
Cibiem, Inc.UnknownHypertension,EssentialAustralia, Czechia, Germany
-
NoblewellCompleted
-
NoblewellCompletedSystolic Heart Failure | Peripheral Chemoreceptor HypersensitivityPoland
-
NoblewellCompleted
-
New Mexico Cancer Care AllianceTerminatedIR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung TumorsRecurrent Non-small Cell Lung CancerUnited States
-
Jonsson Comprehensive Cancer CenterCompletedLung CancerUnited States
-
St. Joseph's Healthcare HamiltonActive, not recruitingSmall Renal Masses (SRM)Canada
-
Washington University School of MedicineTerminatedMetastatic Colorectal CancerUnited States
-
University of Michigan Rogel Cancer CenterWithdrawnCarcinoma, HepatocellularUnited States
-
University of Michigan Rogel Cancer CenterTerminatedRenal Cell CarcinomaUnited States